In this article by Allie Nawrat, our co-founder and CEO Ben Zeskind discusses Immuneering’s recent financing of $62m, in an oversubscribed Series B round led by high-profile life science investors. He speaks to the company’s plans for the funding, including support of its internal portfolio, which leverages its proprietary Disease Cancelling Technology platform. In particular, the funding will help the company to advance its lead candidate, IMMI-1-104, an oncology drug focused on the MEK part of the RAS/MAPK pathway expected to be in clinical trials before the end of 2021, as well as continued support of its bioinformatics services business.
